A Phase 1 Study of CRD3874-SI in People With Advanced Sarcoma or Merkel Cell Cancer

Share

Full Title

A Phase I Trial Of CRD3874-SI, a STING Agonist, in Patients with Advanced/Metastatic Sarcoma and Merkel Cell Carcinoma

Purpose

Researchers want to find the best dose of CRD3874-SI to use in people with sarcoma or Merkel cell carcinoma (MCC). The people in this study have sarcoma or MCC that has spread. CRD3874-SI attaches to a type of protein called a STING. This protein encourages immune cells to kill cancer cells, which may slow or stop cancer growth. CRD3874-SI is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have sarcoma or MCC that has grown beyond its original location or metastasized (spread) to another part of the body.
  • Have recovered from the serious side effects of previous therapies before getting CRD3874-SI.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Ciara Kelly’s office at 646-888-4312.

Protocol

23-169

Phase

Phase I (phase 1)

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators

ClinicalTrials.gov ID

NCT06021626